Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Equity (Unaudited)

v3.25.4
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Income/(Loss)
Employees
Common Stock
Executive Officer
Common Stock
Director
Common Stock
Balance, beginning of period (in shares) at Mar. 31, 2024   33,722,225              
Balance, beginning of period at Mar. 31, 2024 $ 474,887 $ 34 $ 243,555 $ (250) $ 288,783 $ (57,235)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             56,614 87,782 7,241
Stock compensation expense 1,065   1,065            
Repurchase of employee stock units on vesting (2,995)   (2,995)            
Repurchase of shares under authorized program (in shares)   (49,341)              
Repurchase of shares under authorized program (1,579)     (1,579)          
Net income 8,511       8,511        
Foreign currency translation adjustment (3,879)         (3,879)      
Other (30)   1     (31)      
Balance, end of period (in shares) at Jun. 30, 2024   33,824,521              
Balance, end of period at Jun. 30, 2024 475,980 $ 34 241,626 (1,829) 297,294 (61,145)      
Balance, beginning of period (in shares) at Mar. 31, 2024   33,722,225              
Balance, beginning of period at Mar. 31, 2024 474,887 $ 34 243,555 (250) 288,783 (57,235)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 36,544                
Foreign currency translation adjustment (18,291)                
Balance, end of period (in shares) at Dec. 31, 2024   33,708,205              
Balance, end of period at Dec. 31, 2024 488,685 $ 34 245,211 (6,440) 325,328 (75,448)      
Balance, beginning of period (in shares) at Jun. 30, 2024   33,824,521              
Balance, beginning of period at Jun. 30, 2024 475,980 $ 34 241,626 (1,829) 297,294 (61,145)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             924   5,586
Stock compensation expense 1,511   1,511            
Repurchase of employee stock units on vesting (18)   (18)            
Repurchase of shares under authorized program (in shares)   (75,752)              
Repurchase of shares under authorized program (2,260)     (2,260)          
Net income 9,494       9,494        
Foreign currency translation adjustment 5,587         5,587      
Other (7)         (7)      
Balance, end of period (in shares) at Sep. 30, 2024   33,755,279              
Balance, end of period at Sep. 30, 2024 490,287 $ 34 243,119 (4,089) 306,788 (55,565)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in exercise of stock options 632   632            
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             33,753 911 4,025
Stock compensation expense 1,470   1,470            
Repurchase of employee stock units on vesting (10)   (10)            
Repurchase of shares under authorized program (in shares)   (85,763)              
Repurchase of shares under authorized program (2,351)     (2,351)          
Net income 18,539       18,539        
Foreign currency translation adjustment (19,999)         (19,999)      
Other 117       1 116      
Balance, end of period (in shares) at Dec. 31, 2024   33,708,205              
Balance, end of period at Dec. 31, 2024 $ 488,685 $ 34 245,211 (6,440) 325,328 (75,448)      
Balance, beginning of period (in shares) at Mar. 31, 2025 33,243,370 33,243,370              
Balance, beginning of period at Mar. 31, 2025 $ 495,315 $ 33 246,201 (20,388) 342,298 (72,829)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             75,380 100,933 5,058
Stock compensation expense 1,482   1,482            
Repurchase of employee stock units on vesting (3,336)   (3,336)            
Repurchase of shares under authorized program (in shares)   (364,698)              
Repurchase of shares under authorized program (9,767)     (9,767)          
Net income 8,581       8,581        
Foreign currency translation adjustment 17,034         17,034      
Other 1   1            
Balance, end of period (in shares) at Jun. 30, 2025   33,060,043              
Balance, end of period at Jun. 30, 2025 $ 509,310 $ 33 244,348 (30,155) 350,879 (55,795)      
Balance, beginning of period (in shares) at Mar. 31, 2025 33,243,370 33,243,370              
Balance, beginning of period at Mar. 31, 2025 $ 495,315 $ 33 246,201 (20,388) 342,298 (72,829)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 41,826                
Foreign currency translation adjustment $ 15,456                
Balance, end of period (in shares) at Dec. 31, 2025 32,845,065 32,845,065              
Balance, end of period at Dec. 31, 2025 $ 538,702 $ 33 248,080 (36,162) 384,124 (57,373)      
Balance, beginning of period (in shares) at Jun. 30, 2025   33,060,043              
Balance, beginning of period at Jun. 30, 2025 509,310 $ 33 244,348 (30,155) 350,879 (55,795)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in exercise of stock options 72   72            
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             1,365   4,980
Issuance of common stock in exercise of stock option (in shares)   5,074              
Stock compensation expense 1,883   1,883            
Repurchase of employee stock units on vesting (16)   (16)            
Repurchase of shares under authorized program (in shares)   (236,427)              
Repurchase of shares under authorized program (6,007)     (6,007)          
Net income 14,954       14,954        
Foreign currency translation adjustment (4,966)         (4,966)      
Balance, end of period (in shares) at Sep. 30, 2025   32,835,035              
Balance, end of period at Sep. 30, 2025 515,230 $ 33 246,287 (36,162) 365,833 (60,761)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to employees, executive officers and directors (in shares)             693   4,297
Issuance of common stock in exercise of stock option (in shares)   5,040              
Stock compensation expense 1,838   1,838            
Repurchase of employee stock units on vesting (46)   (46)            
Net income 18,291       18,291        
Foreign currency translation adjustment 3,388         3,388      
Other $ 1   1            
Balance, end of period (in shares) at Dec. 31, 2025 32,845,065 32,845,065              
Balance, end of period at Dec. 31, 2025 $ 538,702 $ 33 $ 248,080 $ (36,162) $ 384,124 $ (57,373)